Drugs that remove amyloid plaques may have controversial and potentially insufficient or too late positive results on cognition.

“none of that matters if if you're removing amyloid if the people aren't any better or if they're continuing to get worse you know that's what was happening with the mild to moderate group um you know the original solinazimab trials um you know people just kept getting worse because they're they already had enough neurodegeneration and other pathology now going on in the brain that the whether the amyloid was there anymore didn't matter”

“and none of that matters if if you're removing amyloid if the people aren't any better or if they're continuing to get worse you know that's what was happening with the mild to moderate group um you know the original salon asmab trials um you know people just kept getting worse because they're they already had enough neurodegeneration and other pathology now going on in the brain that whether the amyloid was there anymore it didn't matter”

“so the family is affected it's good that we have a drug that can remove to some extent the plaques and there's evidence of that what is obese a bit less a bit more controversial is the uh the impact on cognition so there's some some you know Improvement but it's not what you would hope for um so which goes back to okay uh targeting amidoid only is probably not the way to go um and probably not sufficient or might be too late also”